Toralgen is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics. Our unique poly-bile nanoparticle platform eliminates the challenges of oral delivery in one simple to fabricate nanopill. These nanopills also localize delivery of drug agents and potentially improve efficacy and safety of a wide range of therapies. Toralgen currently has two candidates in preclinical testing for oral delivery of diabetes agents. Toralgen collaborates with leading pharmaceutical companies to apply our targeted delivery technology across a wide range of therapeutic areas, molecule types and routes of administration.
Location: United States, Indiana, Indianapolis
Employees: 11-50
Total raised: $10.2M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | VisionTech... | visiontech... |
| - | Solyco Cap... | solycocapi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.01.2022 | Seed | $1.9M | - |
| - | Seed | $8.3M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Emil | Joseph, Ph... | Formulatio... | linkedin.c... | - | e*****h@to... |
Mentions in press and media 2
| Date | Title | Description |
| 19.01.2022 | VisionTech Portfolio Company Toralgen Closes $1.9M Seed Funding Round | INDIANAPOLIS, Ind. (September 10, 2019) – – Toralgen, Inc., an Indiana-based biotechnology company, announced the closure of its seed funding round, raising more than $1.9 million. Participants in the round include VisionTech Angels, Elevat... |
| - | VisionTech Portfolio Company Toralgen Closes $8.3 Million Seed Funding Round | INDIANAPOLIS, Indiana (December 14, 2020) – Toralgen, an Indiana-based biotechnology company has announced the successful completion of its second seed funding round, raising a total of $8.3 million. The preclinical stage company will use t... |